Saba Capital Management’s Allergan plc AGN Stock Holding History

Saba Capital Management’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-134,900	Closed	-$28.3M	–	114
2016 Q4	$28.3M	Buy	+134,900	New	+$27.9M	2.88%	9

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Saba Capital Management's AGN Position: Q2 2017 in Review

Saba Capital Management sold out of Allergan plc (AGN) in Q2 2017, closing a stake of 20,203 shares — an estimated $4.83M sold.

Saba Capital Management first reported a position in AGN in Q4 2016 and held it in 2 quarters. The position peaked at $32.7M in Q4 2016. 1,115 funds tracked by Wall St. Rank hold AGN as of Q2 2017.

Saba Capital Management reported no remaining Allergan plc position as of Q2 2017 after selling out during the quarter.
Saba Capital Management sold 20,203 Allergan plc shares in Q2 2017, an estimated $4.83M.
Saba Capital Management first reported a position in Allergan plc in Q4 2016 and held it in 2 quarters.
Saba Capital Management's Allergan plc position peaked at $32.7M in Q4 2016.
1,115 funds tracked by Wall St. Rank held Allergan plc as of Q2 2017.

Based on Saba Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.